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S180 Oral Presentations23of 25 patients (92%), seeTable 1 for patient data summary. In order
to gain insight into themechanismof this enhancedmobilization, a pi-
lot study investigating gene expression analysis was performed on
CD341 cells purified from frozen control apheresis samples, compar-
ing samples from Vel –mob (n5 7)vs. G-CSF1 CTX(n5 8). A sig-
nificant change in the expression of genes associated with the
following canonical pathways was observed: docosahexaenoic acid sig-
naling, angiopoietin signaling and the molecular mechanisms of can-
cer. In relationship to SDF-1 signaling, there was a 1.44 fold increase
(p# 0.05) inCXCR4mRNA isolated fromCD341 cells in pts treated
with vel-mob when compared to CD341 cells isolated fromGCSF1
CTX treated pts. SDF-1 peripheral blood plasma levels were then
measured in vel-mob treated pts (n 5 7) and compared to the levels
in GCSF alone (n 5 8) treated pts. The mean SDF-1 level in vel-
mob treated pts was significantly decreased (p 5 0.0012) when com-
pared to GCSF alone treated pts (1319 pg/ml vs 2225 pg/ml). Vel-
mob is a novel mobilization regimen that produces very high and pre-
dictable CD341 yields. Vel-mob modulates SDF-1 protein levels in
plasma, CXCR4 gene expression in CD341 cells. We have also iden-
tified important canonical pathways that may be associated with im-
proved mobilization.PEDIATRIC DISORDERS
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Rationale:The post transplant infusion of donor lymphocytes (DLI)
has been used to increase alloreactivity against residual
host hematopoiesis in malignant diseases after stem cell transplanta-
tion (SCT).DLI can treat impending rejection, prevent relapse in the
face of decreasing donor chimerism or even treat overt relapse in
some forms of leukemia. However the risk of inducing GVHD after
DLI has limited its use after allogeneic SCT for non malignant
disorders such as primary immunodeficiency diseases (PID).
Methods: PID patients with decreasing donor chimerism despite dis-
continuation of immunosuppression were treated with DLI. The ini-
tial dose of CD31 cells per kg body weight was up to 5*105 for
matched sibling donors (MSD), 1*105 for matched unrelated donors
(MUD) and 2.5*104 for haploidentical family donors (MMFD) in
the absence of GVHD. Patients were to receive additional DLI at 4-
6 week intervals in increasing doses until either GVHD or a stabiliza-
tion/reversal of mixed chimerism was observed.
Results: Ten patients (1 XLP, 2 SCID, 7 WAS) experienced de-
creasing donor chimerism at a median of 94 days (range 62-180
days) after myeloablative (n 5 8, non-SCID) or reduced intensity
(n 5 2, SCID) conditioning SCT from MSD (n 5 1), MUD (n 5
7) or MMFD (n 5 2). None of the patients had had pretransplant
maternal engraftment. They received DLI from their original do-
nors at a median of 120 days (78-366) after SCT. At a median follow
up of 779 days (41-3807) after first DLI and amedian of 5DLI (2-14)
we observed a stabilization of mixed chimerism in 5 patients and im-
provement in 5. None experienced complete rejection or returned to
full donor chimerism. Of note, none of the patients experienced
GVHD of any grade.
Conclusion: DLI after SCT for PID is feasible and may be able to
halt impending rejection. This observation may be especially impor-
tant in the light of an increasing use of reduced intensity condition-
ing regimes with presumably a higher incidence of graft failure and
the fact that many PID can be considered cured even with stable,
low level donor chimerism. We propose a graded dosing regimen
of CD31 cells depending on donor/recipient HLA disparity to min-
imize the risk for DLI induced GVHD, which appeared to be safe
and effective in our patients.73
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Background: Therapeutic drug monitoring (TDM) guided dosing
of busulfan is associated with higher event free survival rates due
to less graft-failure/relapses and lower toxicity in hematological
stem cell transplantation (HSCT). The observed differences in
plasma exposures of intravenously administered busulfan to children
may be related with age, or diseases like immune deficiencies. The
question is whether a more predictable exposure can be obtained
by individualization of busulfan dosing in pediatric HSCT. This
study aims to predict the growth related developmental changes in
the pharmacokinetics (PK) of busulfan, using an extensive covariate
analysis, in order to design an individualized dosing regimen.
Methods: In this retrospective multicentre study, 245 patients were
included, ranging between 1 month and 26 years of age. All patients
intravenously received busulfan-based conditioning combined with
therapeutic drug monitoring (TDM). Data were gathered from
four pediatric centers. Demographics, diagnosis, concomitant med-
ication, hematological and clinical chemistry parameters were used
as covariates, using linear and allometric correlations. NONMEM
was used for data and covariates analysis.
Results: Bodyweight significantly influenced the PK of busulfan in
a nonlinear relation. The other evaluated covariates did not influence
the pharmacokinetic parameters. An allometric scaling method was
used to estimate the clearance of each individual, resulting in
the function for clearance: 2.94L/h *(BWi/15kg)
exp a. Based on
objective function, diagnostics and root mean square error, the
model with ‘‘exp a’’ as one single exponent was inferior compared
to a bodyweight-dependent exponent, with a function; exp a 5
1.96*BW20.234. This model resulted in a scaling exponent of 1.51
in neonates (BW 3-5 kg) decreasing to 0.65 in young adults (BW
80-109 kg). The volume of distribution was allometrically scaled
with one single exponent of 0.87. Based upon this final model
a new dosing regimen was designed to obtain an AUC of 95 mg*h/
L for myeloablative or 45 mg*h/L for non-myeloablative regimens.
Conclusions: This population PK model for busulfan in patients
ranging between 1 month and 26 years of age, describes the PK pa-
rameters of busulfan using a continuous non-linear function depend-
ing on bodyweight. The model-derived individualized dosing
regimen, which is expected to lead to a more predictable exposure
of busulfan in each child, will be prospectively evaluated.74
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Myeloablative (MA) SCT is curative of SCD, and children with
stable donor engraftment no longer experience SCD symptoms
(Walters et al, BBMT 2009), but quality of life may be diminished
by MA SCT related organ toxicity. RTC regimens may potentially
enhance preservation of organ function in patients with SCD. Be-
tween 8/27/2004 and 3/2/10, 18 (16M: 2F) patients with symptom-
atic SCD underwent RTC SCT. Conditioning was Busulfan (4mg/
kg  4d # 4 yrs and 12.8mg/kg  4d . 4 yrs), Fludarabine
(30mg/m2  6d), and Alemtuzumab (2mg/m2  1d, 6mg/m2  2d,
and 20mg/m2  2d). Donor sources: 8-6/6 related bone marrow,
2-6/6 related cord blood (CB), 1-6/6 unrelated CB, 4-5/6 unrelated
Oral Presentations S181CB, and 3-4/6 unrelated CB. Tacrolimus and mycophenolate mofe-
til were used as GVHD prophylaxis (Bhatia/Cairo et al, BBMT
2009) and phenytoin or levetiracetam as seizure prophylaxis for
180 days post-SCT. Organ function testing (MRI/MRA, ECHO,
and PFT) was done pre-SCT and 1 and 2 yrs post-SCT in evaluable
patients. The median follow up is 2.3 yrs (0.6-6.1 yrs). The OS, EFS,
and median 1 and 2 year donor chimerism (WB/CD71) are 83%,
78%, 93/90% and 94/95%, respectively (Bhatia/Cairo et al, ASH
2010). Of the 15 evaluable patients, 9 and 7 patients had a repeat
MRI at 1 and 2 yrs, respectively. All had stable or improved MRI
with the exception of 1 pt who had an embolic CVA on MRI 7
months post-SCTwhich resolved one month later. Sixteen of 18 pa-
tients had pre-SCT ECHO and of those, 3 were noted to have mild
to moderate tricuspid regurgitation (TR). Of those three patients,
two were evaluable at 1 and 2 yrs post-SCT, and were noted to
have improvement in degree of TR, which was noted to be trivial
in one, and trivial to mild in the other. Of evaluable patients at 1
(n 5 9) and 2 yrs (n 5 7) post-SCT, all were noted to have stable
or improving TR with no patient demonstrating evidence of pulmo-
nary hypertension. All patients greater than 8 yrs of age underwent
PFTs. 11 patients had pre-SCT PFTs with 2/11 having restrictive
disease and 1/11 having obstructive disease. Of the nine patients
who were evaluable for comparison before and after SCT, the
mean predicted FVC changed from 90 6 23% to 93.5 6 16% and
the mean predicted FEV1 changed from 876 29% to 906 18% af-
ter transplantation. In conclusion, RTC SCT effectively promoted
stable donor engraftment in SCD pts and was associated with stable
or improved organ stability function at 2 years post-SCT.
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NONMYELOABLATIVE CONDITIONING FOLLOWED BY ALLOGENEIC
MARROW GRAFTS FOR TREATMENT OF PRIMARY IMMUNE DEFICIENCY
DISORDERS: PRELIMINARY RESULTS OF A PHASE II STUDY
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Rawlings, D.J.2, Skoda-Smith, S.2, Ochs, H.2, Storb, R.1,2,Table 1. Pre-transplant risk factors and survival among 23 patients
geneic marrow grafts for high-risk PIDD
Patient # Diagnosis Age (yr)/Gender
1 SCID 1.4/F Parainfluenza, Rhinovirus, P
2 X-SCID 0.5/M CMV reactivation
3 X-SCID 0.8/M Adenovirus, PCP, FTT
4 SCID 1.9/M Disseminated CMV disease
5 SCID 1.2/F Disseminated CMV disease
6 SCID 0.9/M PCP, Influenza B, Rhinoviru
7 SCID 1.0/F Disseminated adenovirus w
8 SCID 0.4/M Parvovirus, FTT
9 Complete DiGeorge 0.4/M Seizures, FTT
10 CID 9.8/F CMV reactivation, chronic
hyperammonemia and e
tubular acidosis, polyarti
FTT
11 CID 0.7/F Enterovirus pneumonia (m
12 CID 2.9/M Bronchitis, recurrent pneu
13 CVID 24.7/F CMV reactivation, Candida
disease with portal HTN
14 CGD 26.5/M Pulmonary Scopulariopsis,
15 CGD 10.7/M Invasive pulmonary Asperg
16 IPEX 16.9/M EBV LPD of the lungs & gu
17 CHH 2.9/F Enterovirus, Norovirus, Hi
FTT
18 CHH 8.7/F CMV reactivation, chronic
19 HLH 2.7/M Pneumonia, h/o multi-syste
HCT
20 Congenital Neutropenia 3.5/M Primary EBV infection
21 HLH 0.6/F HLH
22 ADA-SCID 0.7/M Recurrent viral pneumonia
23 CD40LD 11.3/M CD40LD, s/p colectomy du
CD40LD5 CD40 ligand deficiency; CGD5chronic granulomatous disease; CH
variable immunodeficiency; EBV-LPD5Epstein-Barr virus lymphoproliferative d
tus; HLH5 hemophagocytic lymphohistiocytosis; h/o5history of; HTN5hyper
X–linked; PCP5pneumocystis carnii pneumonia; (S)CID5(severe) combined i
tosystemic shunt, yr5year. Patients 21, 22 and 23 received Alemtuzumab as p
> Alive; †Dead; #NumberWoolfrey, A.1,2 1Fred Hutchinson Cancer Research Center; 2University
of Washington School of Medicine; 3University of Washington School of
Public Health; 4Oregon Health & Sciences University; 5Vanderbilt
University; 6Children’s Hospital & Research Ctr, Oakland
Myeloablative conditioning regimens may cause life threatening
transplant related toxicities in patients with Primary Immune Defi-
ciency Disorders (PIDD), particularly in patients with co-morbid
conditions. Previously we reported the outcomes of a phase I study
using nonmyeloablative conditioning in 14 high-risk patients with
PIDD and observed 3-year survival and transplant related mortality
(TRM) of 62% and 23%, respectively. Although encouraging, the
incidence of chronic GVHDwas 47% at 1 year, which is an undesir-
able outcome for patients with nonmalignant diseases. We reasoned
that the incidence of GVHD might be reduced by replacing PBSC
with marrow; however, our previous experience showed marrow to
be associatedwith a higher risk of graft rejection.Therefore our stan-
dard nonmyeloablative regimen of 90 mg/m2 fludarabine and 2 Gy
total body irradiation (TBI) was slightly intensified to include either
Alemtuzumab, or, if Alemtuzumab was contraindicated, an
additional 2 Gy TBI.
Twenty-three patients with PIDD and significant underlying seri-
ous infections and/or organ dysfunction (table 1) were given HLA-
matched related (n5 10) or unrelated (n5 13) marrow grafts follow-
ing nonmyeloablative conditioning modified with either Alemtuzu-
mab (n 5 3) or 4 Gy TBI (n 5 20). All patients received
mycophenolate mofetil and cyclosporine for postgrafting immuno-
suppression. Of the 20 patients evaluable, 18 had mixed (6-49%, n
5 1; 50-94%; n 5 10) or full (. 95%; n 5 7) donor CD31 T-cell
chimerism. Two patients had graft rejection and survive disease-
free following 2nd successful transplantation. The 2-year cumulative
incidence of chronic GVHD was 22%. With a median follow-up of
26.8 months, the 2-year survival was 76% and the day 200 and 2-year
TRM were 14% and 24%, respectively. Four patients died of pre-
existing infections and/or organ dysfunction and one patient died
of GVHD. Six patients were not evaluable for disease response due
to short follow-up (n 5 1), 2nd HCT (n 5 2), or early death (n 5who received nonmyeloablative conditioning followed by allo-
Pre-transplant Risk Factors Survival (months)
CP, FTT >48.7
>45.1
>36.0
with pneumonitis, myocarditis, nephritis, and hepatitis, FTT >27.8
with pneumonitis, adenovirus pneumonitis, PCP, FTT †Day +1
s, FTT †7.5
ith hepatitis, FTT †Day +15
>Day +4
>23.7
lung disease, h/o fulminant hepatic failure with
ncephalopathy, h/o acute renal failure with persistent renal
cular arthritis, Moraxella catarrhalis sinusitis and pneumonia,
>27.6
echanical ventilation dependent before and at time of HCT) †1.4
monia >2.3
pneumonia, lymphocytic interstitial pneumonitis, liver
of unknown etiology s/p TIPS procedure, IDDM
>11.1
FTT >26.9
illosis, Protein losing enteropathy >15.0
t, chronic interstitial lung disease, IDDM >26.0
rschsprung’s disease s/p total colectomy, TPN dependent, >4.3
lung disease, hemolytic anemia >4.3
m organ failure - shock, renal failure – dialysis dependent at †7.4
>45.1
>43.4
s, FTT >42.0
e to pre HCT dysplasia throughout colon >35.7
H5cartilage hair hypoplasia; CMV5cytomegalovirus; CVID5common
isease; FTT5failure to thrive; IDDM5insulin dependent diabetes melli-
tension; IPEX5immune dysregulation-polyendocrinopathy-enteropathy-
mmune deficiency; s/p5status post; TIPS5transjugular intrahepatic por-
art of the conditioning regimen.
